Masanobu Oshima Selected Research

Dinoprostone (PGE2)

1/2019	Interleukin 1 Up-regulates MicroRNA 135b to Promote Inflammation-Associated Gastric Carcinogenesis in Mice.
1/2018	The inflammatory microenvironment that promotes gastrointestinal cancer development and invasion.
12/2017	Requisite role of vasohibin-2 in spontaneous gastric cancer formation and accumulation of cancer-associated fibroblasts.
11/2017	A novel role for OATP2A1/SLCO2A1 in a murine model of colon cancer.
1/2017	Nardilysin regulates inflammation, metaplasia, and tumors in murine stomach.
1/2017	Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity.
4/2016	Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways.
3/2016	Myeloid Differentiation Factor 88 Signaling in Bone Marrow-Derived Cells Promotes Gastric Tumorigenesis by Generation of Inflammatory Microenvironment.
1/2015	Canolol inhibits gastric tumors initiation and progression through COX-2/PGE2 pathway in K19-C2mE transgenic mice.
9/2010	Mouse models of gastric tumors: Wnt activation and PGE2 induction.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masanobu Oshima Research Topics

Disease

67	Neoplasms (Cancer) 01/2022 - 01/2002
42	Carcinogenesis 01/2022 - 01/2002
28	Stomach Neoplasms (Stomach Cancer) 02/2020 - 10/2005
16	Inflammation (Inflammations) 01/2022 - 10/2005
9	Colonic Neoplasms (Colon Cancer) 01/2022 - 12/2003
9	Gastritis 01/2019 - 10/2009
8	Metaplasia 01/2019 - 04/2004
7	Hyperplasia 01/2019 - 04/2004
6	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 04/2007
6	Carcinoma (Carcinomatosis) 12/2020 - 10/2006
6	Infections 01/2019 - 04/2002
5	Adenoma (Adenomas) 01/2022 - 01/2002
5	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2011 - 01/2002
5	Polyps 10/2005 - 01/2002
4	Adenocarcinoma 10/2009 - 01/2002
3	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2021 - 03/2011
3	Colitis 01/2019 - 02/2008
3	Hamartoma 09/2010 - 04/2009
3	Hepatocellular Carcinoma (Hepatoma) 11/2009 - 04/2002
3	Helicobacter Infections 06/2008 - 04/2004
3	Intestinal Polyps 10/2005 - 01/2002
2	Melanoma (Melanoma, Malignant) 01/2022 - 06/2004
2	Glioblastoma (Glioblastoma Multiforme) 12/2020 - 01/2019
2	Brain Neoplasms (Brain Tumor) 01/2019 - 10/2009
2	Neoplasm Metastasis (Metastasis) 01/2018 - 06/2004
2	Bacterial Infections (Bacterial Infection) 02/2012 - 02/2011
2	Intestinal Polyposis (Polyposis, Intestinal) 08/2003 - 04/2002
1	Microsatellite Instability 01/2022
1	Colitis-Associated Neoplasms 01/2021

Drug/Important Bio-Agent (IBA)

18	Dinoprostone (PGE2)FDA Link 01/2019 - 04/2004
14	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2018 - 01/2002
13	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2002
12	ProstaglandinsIBA 11/2017 - 01/2002
10	CytokinesIBA 01/2021 - 10/2005
10	Prostaglandins EIBA 03/2013 - 08/2003
10	beta CateninIBA 11/2009 - 04/2002
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2011 - 10/2005
5	Interleukin-11 (Interleukin 11)IBA 01/2021 - 03/2009
5	EnzymesIBA 12/2020 - 04/2004
5	spasmolytic polypeptideIBA 01/2019 - 10/2005
5	Messenger RNA (mRNA)IBA 01/2019 - 12/2017
5	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2018 - 02/2012
5	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 03/2013 - 01/2002
4	LigandsIBA 01/2022 - 06/2004
4	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2017
4	Transforming Growth Factor-beta Type II ReceptorIBA 01/2022 - 02/2015
4	CarcinogensIBA 10/2021 - 01/2002
4	Prostaglandin-E SynthasesIBA 10/2015 - 04/2004
3	CateninsIBA 01/2022 - 10/2015
3	InterleukinsIBA 01/2021 - 03/2009
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 03/2009
3	AcidsIBA 02/2020 - 11/2016
3	Toll-Like Receptor 2IBA 01/2019 - 11/2012
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 03/2011
3	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2019 - 10/2015
3	MicroRNAs (MicroRNA)IBA 01/2019 - 03/2013
3	ChemokinesIBA 01/2018 - 06/2004
3	Conditioned Culture MediaIBA 12/2017 - 06/2008
3	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 02/2012 - 01/2002
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 02/2012 - 01/2002
3	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 09/2010 - 04/2009
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2008 - 01/2002
2	InflammasomesIBA 01/2022 - 01/2018
2	CurcuminIBA 12/2020 - 10/2015
2	RNA (Ribonucleic Acid)IBA 12/2020 - 01/2018
2	Pharmaceutical PreparationsIBA 01/2019 - 01/2018
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2018 - 10/2005
2	Estrogens (Estrogen)FDA Link 01/2018 - 01/2018
2	EpiregulinIBA 12/2017 - 04/2011
2	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 01/2017 - 12/2008
2	Biomarkers (Surrogate Marker)IBA 03/2016 - 02/2015
2	AntibodiesIBA 01/2015 - 06/2004
2	Bromodeoxyuridine (BrdU)IBA 01/2012 - 03/2010
2	Dextran SulfateIBA 03/2011 - 02/2008
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2009 - 04/2007
2	Antisense RNA (Anti-Sense RNA)IBA 06/2004 - 12/2003
1	Toll-Like Receptor 9IBA 01/2022
1	Pattern Recognition ReceptorsIBA 01/2022
1	Frizzled ReceptorsIBA 01/2022
1	NF-kappa B (NF-kB)IBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Mitogen-Activated Protein KinasesIBA 01/2022
1	Translationally-Controlled 1 Tumor ProteinIBA 01/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Untranslated RNA (Noncoding RNA)IBA 01/2021
1	Immunologic Factors (Immunomodulators)IBA 01/2021
1	Serine (L-Serine)FDA Link 12/2020
1	protein phosphatase 6IBA 12/2020
1	Threonine (L-Threonine)FDA Link 12/2020
1	Phosphoprotein Phosphatases (Phosphatases, Protein)IBA 12/2020
1	1,2-cyclohexanediolIBA 10/2020
1	trametinibIBA 01/2020
1	Interleukin-23 (Interleukin 23)IBA 01/2020

Therapy/Procedure

6	Therapeutics 01/2021 - 10/2013
3	Chemoprevention 01/2019 - 02/2008
2	Transplantation 01/2022 - 01/2018
2	Lasers (Laser) 01/2019 - 01/2018
2	Drug Therapy (Chemotherapy) 01/2018 - 10/2015
1	Heterologous Transplantation (Xenotransplantation) 10/2021
1	Immunotherapy 01/2021